FINWIRES · TerminalLIVE
FINWIRES

NEXTDC社、約20億豪ドル規模の劣後ハイブリッド証券の卸売販売を完了

By

-- NEXTDC(ASX:NXT)は、オーストラリア証券取引所への木曜日の提出書類によると、17億豪ドルの劣後ハイブリッド証券の卸売募集を完了した。この募集は、当初の10億豪ドルシリーズと、7億豪ドルの繰延引受シリーズから構成される。 提出書類によると、カナダを拠点とする投資グループ、ラ・ケスが、当初シリーズで10億豪ドル、繰延引受シリーズで7億豪ドルの出資を約束した。 提出書類によると、当初シリーズの決済および発行は5月15日に行われる予定であり、繰延引受シリーズは、慣例的な前提条件を満たすことを条件として、5月6日から12ヶ月以内に発行される可能性がある。

Related Articles

Asia

StarHub's Net Attributable Profit Falls 81% in Q1

StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.

$SGX:CC3
Asia

Meesho Narrows Consolidated Loss in Fiscal Q4

Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.

$BOM:544632$NSE:MEESHO
Asia

Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug

Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.

$SHE:000661
NEXTDC社、約20億豪ドル規模の劣後ハイブリッド証券の卸売販売を完了 | FINWIRES